191 related articles for article (PubMed ID: 19468267)
1. Advancements in the molecular pathogenesis of myelodysplastic syndrome.
Epling-Burnette PK; List AF
Curr Opin Hematol; 2009 Mar; 16(2):70-6. PubMed ID: 19468267
[TBL] [Abstract][Full Text] [Related]
2. Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia.
Bidet A; Dulucq S; Smol T; Marceau-Renaut A; Morisset S; Coiteux V; Noël-Walter MP; Nicolini FE; Tigaud I; Luquet I; Struski S; Gaillard B; Penther D; Tondeur S; Nadal N; Hermet E; Véronèse L; Réa D; Gervais C; Theisen O; Terré C; Cony-Makhoul P; Lefebvre C; Gaillard JB; Radford I; Vervaeke AL; Barin C; Chapiro E; Nguyen-Khac F; Etienne G; Preudhomme C; Mahon FX; Roche-Lestienne C;
Haematologica; 2019 Jun; 104(6):1150-1155. PubMed ID: 30573507
[TBL] [Abstract][Full Text] [Related]
3. Myelodysplastic syndromes.
Cilloni D; Messa F; Carturan S; Arruga F; Defilippi I; Messa E; Gottardi E; Saglio G
Ann N Y Acad Sci; 2004 Dec; 1028():400-8. PubMed ID: 15650265
[TBL] [Abstract][Full Text] [Related]
4. Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome.
Kennedy JA; Ebert BL
J Clin Oncol; 2017 Mar; 35(9):968-974. PubMed ID: 28297619
[TBL] [Abstract][Full Text] [Related]
5. Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes.
Nakajima H
Intern Med; 2021 Jan; 60(1):15-23. PubMed ID: 32009100
[TBL] [Abstract][Full Text] [Related]
6. MicroRNAs in the pathogenesis of myelodysplastic syndromes and myeloid leukaemia.
Song SJ; Pandolfi PP
Curr Opin Hematol; 2014 Jul; 21(4):276-82. PubMed ID: 24870972
[TBL] [Abstract][Full Text] [Related]
7. The genetic and molecular pathogenesis of myelodysplastic syndromes.
Shallis RM; Ahmad R; Zeidan AM
Eur J Haematol; 2018 Sep; 101(3):260-271. PubMed ID: 29742289
[TBL] [Abstract][Full Text] [Related]
8. Mutations in myelodysplastic syndromes: Core abnormalities and CHIPping away at the edges.
Caponetti GC; Bagg A
Int J Lab Hematol; 2020 Dec; 42(6):671-684. PubMed ID: 32757473
[TBL] [Abstract][Full Text] [Related]
9. [Recent advances in the treatment of myelodysplastic syndromes].
Gelsi-Boyer V; Vey N
Rev Med Interne; 2006 Aug; 27(8):600-9. PubMed ID: 16713027
[TBL] [Abstract][Full Text] [Related]
10. Uncoding the genetic heterogeneity of myelodysplastic syndrome.
Lindsley RC
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):447-452. PubMed ID: 29222292
[TBL] [Abstract][Full Text] [Related]
11. [Recent advances of molecular mechanisms influencing prognosis of myelodysplastic syndrome - review].
Guo J; Chang CK; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):1020-4. PubMed ID: 22931676
[TBL] [Abstract][Full Text] [Related]
12. [New tools and treatments in myelodysplastic syndromes].
Cluzeau T; Fenaux P
Rev Med Interne; 2013 Mar; 34(3):159-67. PubMed ID: 22766158
[TBL] [Abstract][Full Text] [Related]
13. [Treatment for myelodysplastic syndromes and future perspectives in the genomic era].
Maeda T
Rinsho Ketsueki; 2021; 62(8):1038-1049. PubMed ID: 34497190
[TBL] [Abstract][Full Text] [Related]
14. Dynamics of telomere erosion and its association with genome instability in myelodysplastic syndromes (MDS) and acute myelogenous leukemia arising from MDS: a marker of disease prognosis?
Sieglová Z; Zilovcová S; Cermák J; Ríhová H; Brezinová D; Dvoráková R; Marková M; Maaloufová J; Sajdová J; Brezinová J; Zemanová Z; Michalová K
Leuk Res; 2004 Oct; 28(10):1013-21. PubMed ID: 15289012
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow mononuclear cell telomere length in acute myeloid leukaemia and high-risk myelodysplastic syndrome.
Warny M; Helby J; Sengeløv H; Nordestgaard BG; Birgens H; Bojesen SE
Eur J Haematol; 2019 Mar; 102(3):218-226. PubMed ID: 30427547
[TBL] [Abstract][Full Text] [Related]
16. The multifaceted nature of myelodysplastic syndromes: clinical, molecular, and biological prognostic features.
Greenberg PL
J Natl Compr Canc Netw; 2013 Jul; 11(7):877-84; quiz 885. PubMed ID: 23847221
[TBL] [Abstract][Full Text] [Related]
17. Cytogenetics in benzene-associated myelodysplastic syndromes and acute myeloid leukemia: new insights into a disease continuum.
Irons RD; Kerzic PJ
Ann N Y Acad Sci; 2014 Mar; 1310():84-8. PubMed ID: 24611724
[TBL] [Abstract][Full Text] [Related]
18. Pathologic Features of Down Syndrome Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML0431.
Mast KJ; Taub JW; Alonzo TA; Gamis AS; Mosse CA; Mathew P; Berman JN; Wang YC; Jones HM; Campana D; Coustan-Smith E; Raimondi SC; Hirsch B; Hitzler JK; Head DR
Arch Pathol Lab Med; 2020 Apr; 144(4):466-472. PubMed ID: 31429606
[TBL] [Abstract][Full Text] [Related]
19. Novel therapeutic strategies in myelodysplastic syndromes: do molecular genetics help?
Chung SS
Curr Opin Hematol; 2016 Mar; 23(2):79-87. PubMed ID: 26825694
[TBL] [Abstract][Full Text] [Related]
20. Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies.
Padron E; Steensma DP
Curr Opin Hematol; 2015 Mar; 22(2):163-70. PubMed ID: 25575034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
